EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Page E Blas iD, Esther San Roman Rodriguez, Heather L Williams, Maren K Levin, Joshua S K Bell, Mariaelena Pierobon, Alexander S Barrett, Emanuel F Petricoin, Joyce A O'Shaughnessy

Cancer Reports · 2024

DOI: 10.1002/cnr2.1954 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Page E Blas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology Research Coordination, Baylor Scott and White Research Institute, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Overexpression of HER2 plays an important role in cancer progression and is the target of multiple therapies in HER2‐positive breast cancer. Recent studies have also highlighted the presence of activating mutations in HER2 , and HER3 that are predicted to enhance HER2 downstream pathway activation in a HER2‐dependent manner.

Methods

In this report, we present two exceptional responses in hormone receptor‐positive, HER2 ‐nonamplified, HER2/HER3 co‐mutated metastatic breast cancer patients who were treated with the anti‐HER2‐directed monoclonal antibodies, trastuzumab and pertuzumab.

Results

Both patients acheived exceptional responses to treatment, suggesting that combined trastuzumab, pertuzumab, and endocrine therapy could be a highly effective therapy for these patients and our observations could help prioritize trastuzumab deruxtecan as an early therapeutic choice for patients whose cancers have activating mutations in HER2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFemaleHumansAntibodies, Monoclonal, HumanizedMutationTrastuzumabReceptor, ErbB-3Erb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

HER2/HER3 co-mutationscancer biologyexceptional respondermetastatic breast cancer

Substanzen

Antibodies, Monoclonal, HumanizedTrastuzumabpertuzumabERBB3 protein, humanReceptor, ErbB-3ERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Clinical Oncology Research Coordination, Baylor Scott and White Research Institute, Dallas, Texas, USA.
  • Department of Translational Science, Tempus Labs Inc., Chicago, Illinois, USA.
  • Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia, USA.
  • Breast Cancer Research Program, Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, Texas, USA.

ORCID-Profile: Page E Blas

Zitieren

APA

Blas, P. E., Rodriguez, E. S. R., Williams, H. L., Levin, M. K., Bell, J. S. K., Pierobon, M., Barrett, A. S., Petricoin, E. F., & O'Shaughnessy, J. A. (2024). Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy. Cancer Reports. https://doi.org/10.1002/cnr2.1954

Vancouver

Blas PE, Rodriguez ESR, Williams HL, Levin MK, Bell JSK, Pierobon M, et al. Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy. Cancer Reports. 2024. doi:10.1002/cnr2.1954

BibTeX
@article{Blas2024,
  author = {Blas, Page E and Rodriguez, Esther San Roman and Williams, Heather L and Levin, Maren K and Bell, Joshua S K and Pierobon, Mariaelena and Barrett, Alexander S and Petricoin, Emanuel F and O'Shaughnessy, Joyce A},
  title = {Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.1954}
}
Kostenlos starten →